No Data
No Data
Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Institutional Investors May Overlook Amgen Inc.'s (NASDAQ:AMGN) Recent US$7.9b Market Cap Drop as Long-term Gains Remain Positive
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Federman & Sherwood Investigates Amgen, Inc. for Data Breach
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.